Valneva (VLA) Panoramica del titolo
Valneva SE, azienda specializzata in vaccini, sviluppa, produce e commercializza vaccini profilattici per malattie infettive con esigenze non soddisfatte. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
VLA Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Valneva SE
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €2.31 |
| Massimo di 52 settimane | €5.42 |
| Minimo di 52 settimane | €2.27 |
| Beta | 1.53 |
| Variazione di 1 mese | -18.01% |
| Variazione a 3 mesi | -40.54% |
| Variazione di 1 anno | -20.00% |
| Variazione a 3 anni | -55.86% |
| Variazione a 5 anni | -80.54% |
| Variazione dall'IPO | -78.91% |
Notizie e aggiornamenti recenti
VLA: Lyme Vaccine Progress Will Support Earnings Despite Chikungunya Setback
Analysts have kept their Valneva price target steady at €3.25, citing updated assumptions for discount rate, revenue growth, profit margins and future P/E that broadly support the prior valuation level. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial results for their 6-valent OspA-based Lyme disease vaccine candidate PF-07307405, with efficacy above 70% in reducing confirmed Lyme cases in two pre specified analyses and no safety concerns identified at the time of analysis.VLA: Lyme Vaccine Progress Will Offset Chikungunya Headwinds Over Time
Analysts have raised their Valneva price target from €2.95 to €3.25, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple as the main factors behind the change. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial data for their investigational 6 valent OspA based Lyme disease vaccine candidate, with efficacy readings in prespecified analyses and Pfizer planning regulatory submissions after reviewing the results and safety profile (Product related announcement).Recent updates
VLA: Lyme Vaccine Progress Will Support Earnings Despite Chikungunya Setback
Analysts have kept their Valneva price target steady at €3.25, citing updated assumptions for discount rate, revenue growth, profit margins and future P/E that broadly support the prior valuation level. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial results for their 6-valent OspA-based Lyme disease vaccine candidate PF-07307405, with efficacy above 70% in reducing confirmed Lyme cases in two pre specified analyses and no safety concerns identified at the time of analysis.VLA: Lyme Vaccine Progress Will Offset Chikungunya Headwinds Over Time
Analysts have raised their Valneva price target from €2.95 to €3.25, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple as the main factors behind the change. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial data for their investigational 6 valent OspA based Lyme disease vaccine candidate, with efficacy readings in prespecified analyses and Pfizer planning regulatory submissions after reviewing the results and safety profile (Product related announcement).
VLA: Vaccine Partnerships And Guidance Will Drive Bullish Repricing Potential
Analysts have nudged their price target on Valneva slightly lower to about €6.96 from roughly €6.99, reflecting updated assumptions around discount rates, revenue growth, profit margins and future price-to-earnings levels. What's in the News Elaris FlexCo signed an exclusive global license agreement for Valneva's Clostridioides difficile vaccine candidate VLA84, with plans to use the antigen technology in a next generation program and potential milestone and royalty payments tied to future development, regulatory and commercial outcomes (Key Developments).
VLA: Future Travel Vaccine Franchise And Real World Data Will Drive Reassessment
Analysts have reaffirmed their €10.00 price target for Valneva, with updated assumptions showing a slightly higher discount rate and profit margin, alongside a lower future P/E, suggesting a more balanced view of risk and earnings potential. What's in the News Valneva issued earnings guidance for 2026, expecting total revenues of €155 million to €170 million, with product sales of €145 million to €160 million.VLA: Future Lyme Vaccine Milestones Will Shape Bullish Repricing Potential
Analysts have adjusted their fair value estimate for Valneva from €6.51 to about €6.99. This change reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples.VLA: Chikungunya Safety Setbacks Will Weigh On Long Term Earnings Potential
Analysts have reduced their price target on Valneva from €3.25 to €2.95, citing updated assumptions for revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Valneva and Instituto Butantan launched a Pilot Vaccination Strategy in Brazil using single shot chikungunya vaccine IXCHIQ, aiming for 20% to 40% coverage of adults aged 18 to 59 in ten municipalities as part of post marketing effectiveness and safety studies (Key Developments).VLA: Future Vaccine Pipeline Progress Will Support Higher Market Reassessment
Analysts have lifted their fair value estimate for Valneva from €9.50 to €10.00, pointing to adjusted assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Valneva decided to voluntarily withdraw the BLA and IND for its chikungunya vaccine IXCHIQ in the US after the FDA suspended the license in August 2025 and later placed the IND on clinical hold following a newly reported foreign serious adverse event that may be plausibly related to vaccination, while causality has not been determined and no active vaccination studies are ongoing (company announcement).VLA: Chikungunya Commercial Uncertainty Will Undermine Long Term Earnings Potential
Analysts have adjusted their price targets for Valneva, with updated assumptions that include a discount rate of 6.76%, revenue growth of 9.16%, a profit margin of 26.93% and a forward P/E of 13.87x, reflecting a recalibration of expectations around the company’s risk profile and earnings outlook. What's in the News Valneva and Serum Institute of India agreed to discontinue their license deal for the single shot chikungunya vaccine, with Valneva regaining full rights to manage supply and commercialization in endemic high risk countries within the funding framework agreed with CEPI and the European Union (Client Announcements).VLA: Higher Long Term Profit Hopes Will Not Offset Rising Risk
Analysts have trimmed their price target for Valneva from €3.75 to €3.25, reflecting higher perceived risk despite more optimistic long term assumptions for revenue growth and profitability. What's in the News Positive Phase 2 antibody persistence and safety data in 304 children for single shot chikungunya vaccine IXCHIQ, supporting full dose selection and planned Phase 3 development in pediatrics (company announcement) Phase 2 Lyme disease vaccine candidate VLA15 shows strong booster response and favorable safety across age groups, reinforcing partnership with Pfizer ahead of planned 2026 BLA and MAA filings, subject to positive Phase 3 results (company announcement) Strategic reorganization to concentrate French operations in Lyon and close the Nantes site.Subdued Growth No Barrier To Valneva SE (EPA:VLA) With Shares Advancing 29%
Oct 01
Is Valneva (EPA:VLA) Using Too Much Debt?
Sep 10Rapid Lyme Vaccine Development And Rising Preventative Healthcare Will Shape Future Markets
Valneva's substantial improvement in net profit margin and sharp reduction in future P/E have led to a notable upward revision in the consensus analyst price target from €6.97 to €7.48. What's in the News Health Canada granted marketing authorization for IXCHIQ, Valneva’s single-dose chikungunya vaccine, for individuals aged 12 years and older, supported by robust antibody persistence and safety data.Valneva SE's (EPA:VLA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Jul 24Upcoming Lyme Vaccine Data Will Unlock Market Opportunities
Potential success of the Lyme disease vaccine could significantly boost future revenue and earnings through strategic regulatory filings and commercialization milestones.Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%
Feb 20Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry
Feb 06Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues
Nov 22€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Nov 10Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive
Sep 19Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 17Rendimenti per gli azionisti
| VLA | FR Biotechs | FR Mercato | |
|---|---|---|---|
| 7D | -3.5% | -0.2% | -1.4% |
| 1Y | -20.0% | 290.9% | 1.9% |
Ritorno vs Industria: VLA ha avuto una performance inferiore rispetto al French Biotechs che ha registrato un rendimento 290.9 % nell'ultimo anno.
Rendimento vs Mercato: VLA ha avuto una performance inferiore al mercato French che ha registrato un rendimento 1.9 % nell'ultimo anno.
Volatilità dei prezzi
| VLA volatility | |
|---|---|
| VLA Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in FR Market | 10.3% |
| 10% least volatile stocks in FR Market | 2.9% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di VLA è stato volatile rispetto al mercato French.
Volatilità nel tempo: La volatilità settimanale ( 13% ) di VLA è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni French.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1998 | 674 | Thomas Lingelbach | valneva.com |
Valneva SE, azienda specializzata in vaccini, sviluppa, produce e commercializza vaccini profilattici per malattie infettive con esigenze non soddisfatte. L'azienda offre IXIARO, un vaccino inattivato derivato da colture di cellule Vero per l'encefalite giapponese, indicato per l'immunizzazione attiva contro l'encefalite giapponese; DUKORAL, un vaccino orale per la prevenzione della diarrea causata da Vibrio cholera o dal batterio Escherichia coli enterotossigeno produttore di tossine termolabili; e IXCHIQ/VLA1553, un vaccino monodose, vivo e attenuato, per la prevenzione della malattia causata dal virus chikungunya. L'azienda sviluppa anche VLA15, un candidato vaccino contro Borrelia, il batterio che causa la malattia di Lyme; S4V2, un candidato vaccino bioconiugato tetravalente contro la shigellosi, un'infezione diarroica causata dal batterio Shigella; VLA1601, un candidato vaccino contro il virus Zika, una malattia virale trasmessa dalle zanzare; VLA1554, un candidato vaccino contro il metapneumovirus umano; VLA84, un candidato vaccino per la prevenzione dell'infezione primaria sintomatica da clostridium difficile; e VLA2112, un candidato vaccino per il trattamento dei pazienti affetti dal virus di epstein-barr.
Valneva SE Riepilogo dei fondamenti
| VLA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €401.72m |
| Utili (TTM) | -€115.19m |
| Ricavi(TTM) | €174.66m |
VLA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| VLA Conto economico (TTM) | |
|---|---|
| Ricavi | €174.66m |
| Costo del fatturato | €192.44m |
| Profitto lordo | -€17.78m |
| Altre spese | €97.41m |
| Utili | -€115.19m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
May 07, 2026
| Utile per azione (EPS) | -0.66 |
| Margine lordo | -10.18% |
| Margine di profitto netto | -65.95% |
| Rapporto debito/patrimonio netto | 168.8% |
Come si è comportato VLA nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/04/30 14:55 |
| Prezzo dell'azione a fine giornata | 2026/04/30 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Valneva SE è coperta da 15 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Vladimira Urbankova | Erste Group Bank AG |
| Simon Scholes | First Berlin Equity Research GmbH |
| Rajan Sharma | Goldman Sachs |